Asymmetric dimethylarginine as an independent risk marker for mortality in ambulatory patients with peripheral arterial disease.
Standard
Asymmetric dimethylarginine as an independent risk marker for mortality in ambulatory patients with peripheral arterial disease. / Böger, Rainer; Endres, H G; Schwedhelm, Edzard; Darius, H; Atzler, Dorothee; Lüneburg, Nicole; von Stritzky, B; Maas, Renke; Thiem, U; Benndorf, Ralf; Diehm, C.
in: J INTERN MED, Jahrgang 269, Nr. 3, 3, 2011, S. 349-361.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Asymmetric dimethylarginine as an independent risk marker for mortality in ambulatory patients with peripheral arterial disease.
AU - Böger, Rainer
AU - Endres, H G
AU - Schwedhelm, Edzard
AU - Darius, H
AU - Atzler, Dorothee
AU - Lüneburg, Nicole
AU - von Stritzky, B
AU - Maas, Renke
AU - Thiem, U
AU - Benndorf, Ralf
AU - Diehm, C
PY - 2011
Y1 - 2011
N2 - Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide (NO) synthesis causing endothelial dysfunction, an early sign of atherogenesis. Symmetric dimethylarginine (SDMA) does not inhibit NO synthases. Peripheral arterial disease (PAD) is a systemic indication of atherosclerosis.
AB - Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide (NO) synthesis causing endothelial dysfunction, an early sign of atherogenesis. Symmetric dimethylarginine (SDMA) does not inhibit NO synthases. Peripheral arterial disease (PAD) is a systemic indication of atherosclerosis.
M3 - SCORING: Journal article
VL - 269
SP - 349
EP - 361
JO - J INTERN MED
JF - J INTERN MED
SN - 0954-6820
IS - 3
M1 - 3
ER -